Novo Nordisk posts strong results, reassures with guidance
Global diabetes care giant, Denmark’s Novo Nordisk (NOV: N) saw its shares gain 4% to 265.80 Danish kroner this morning, after posting a strong set of financials for the third-quarter and nine months of 2014.
Third-quarter net profit rose 1.2% to 6.5 billion kroner ($1.1 billion), on revenue up 8.5% to 22.25 billion kroner. Operating profit for the quarter rose to 8.57 billion kroner, slightly above an average forecast of 8.47 billion kroner in a Reuters poll of analysts. The roll-out of Tresiba (insulin degludec) continues. In Japan, Tresiba now represents 24% of the basal insulin market measured in monthly value market share, the company noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze